Pharmaceutical - Diabetes


Current filters:


Popular Filters

151 to 175 of 401 results

Sanofi temporarily pulls lixisenatide NDA in USA


French drug major Sanofi (Euronext: SAN) this morning (September 12) announced its decision to withdraw…

DiabeteslixisenatideLyxumiaNorth AmericaPharmaceuticalRegulationSanofiZealand Pharma

Depomed expands geographic scope of metformin deal with Merck


USA-based Depomed (Nasdaq: DEPO) says it has expanded the geographic scope of its non-exclusive license…

DepomedDiabetesJanumetLicensingMerck & CometforminPharmaceutical

ThromboGenics gains rights to DME drug


Belgium-based biopharma firm ThromboGenics (Euronext Brussels: THR:BR) has entered into a collaboration…

Bicycle TherapeuticsBiotechnologyDiabetesLicensingOphthalmicsPharmaceuticalThromboGenics

Novo Nordisk falls on loss of two US contracts


Danish insulin giant Novo Nordisk (NOV: N) saw its shares fall 2.8% to 936 Danish kroner yesterday (September…

Bristol-Myers SquibbDiabetesEli LillyMarkets & MarketingNorth AmericaNovo NordiskNovoLogPharmaceuticalVictoza

Merck & Co to co-promote diabetes agent ipragliflozin in Japan


Japanese drug major Astellas Pharma (TYO: 4503) has entered into a co-promotion agreement in Japan with…

Asia-PacificAstellas PharmaDiabetesipragliflozinKotobuki PharmaceuticalLicensingMarkets & MarketingMerck & CoPharmaceutical

Zealand and Lilly to work together on type 2 diabetes and obesity therapies


Denmark's Zealand Pharma (Nasdaq OMX: ZEAL) has announced an exclusive peptide drug R&D collaboration…

DiabetesEli LillyGlobalPharmaceuticalResearchZealand Pharma

Growing diabetes market will attract superior disease control


The expected rise in diabetes is encouraging pharma companies to race to launch type 2 diabetes drugs,…


Sirona Biochem signs LoI with leading Chinese diabetes company


Canada's Sirona Biotech (TSX VENTURE:SBM) has signed a letter of intent to provide an exclusive license…

Asia-PacificBiotechnologyDiabetesFosun PharmaLicensingPharmaceuticalSGLT2Sirona BiochemWanbang Pharma

Three-fold risk of type 2 diabetes in children/youth taking antipsychotics, new study finds


The increased prescribing of antipsychotics for children and youth has heightened concerns that this…


Novo Nordisk makes US appointment; gets appro for NovoPen Echo


Danish insulin giant Novo Nordisk (NOV: N) said late yesterday (August 21) that Jesper Hoiland has been…

DiabetesManagementNorth AmericaNovo NordiskNovoPen EchoPharmaceuticalRegulation

Positive Ph III data for Trajenta in elderly type 2 diabetes patients


Elderly people with type 2 diabetes (T2D) treated for 24 weeks with the dipeptidyl peptidase-4 (DPP-4)…

Boehringer IngelheimDiabetesEli LillyPharmaceuticalResearchTradjentaTrajenta

Positive results with MannKind's type 1 diabetes drug please investors


There was good news for loss-making US drugmaker MannKind (Nasdaq: MNKD), when the company announced…

AfrezzaDiabetesMannKindNorth AmericaPharmaceuticalRegulationResearch

Pfizer links with academia for obesity and diabetes research


As part of a new collaboration, the USA's Sanford-Burnham Medical Research Institute at Lake Nona revealed…


Avanir to promote Merck's diabetes drug Januvia


US drugmaker Avanir Pharmaceuticals (Nasdaq: AVNR) has entered into an exclusive agreement with US drug…

Avanir PharmaceuticalsDiabetesJanuviaMarkets & MarketingMerck & CoNorth AmericaPharmaceutical

Drug developed by UCSF researcher continues to show promise in type 1 diabetes


Teplizumab, an experimental drug designed to block the advance of type 1 diabetes in its earliest stages…

DiabetesEli LillyPharmaceuticalResearchteplizumab

Novo Nordisk first-half boosted by Victoza and modern insulins


Danish insulin giant Novo Nordisk (NOV: N) posted second quarter 2013, showing that earnings before interest…

DiabetesFinancialNovo NordiskPharmaceutical

US PDUFA for GSK diabetes drug delayed


UK pharma giant GlaxoSmithKline (LSE: GSK) revealed on Friday (August 2) that the US Prescription Drug…

albiglutideDiabetesGlaxoSmithKlineNorth AmericaPharmaceuticalRegulation

Boehringer Ingelheim and Eli Lilly launch linagliptin trial


German family-owned drug major Boehringer Ingelheim and US pharma major Eli Lilly (NYSE: LLY) have enrolled…

Boehringer IngelheimDiabetesEli LillyEuropelinagliptinPharmaceuticalResearch

Takeda gains Chinese approval for diabetes drug


Japan's largest drugmaker, Takeda Pharmaceutical (TYO: 4502), says that the China Food and Drug Administration…

Asia-PacificDiabetesNesinaPharmaceuticalRegulationSanofiTakeda Pharmaceuticals

151 to 175 of 401 results

Company Spotlight



Back to top